Správy od Ipsen

Ipsen’s Chief Medical Officer Sandra Silvestri argues that deep understanding of disease and ongoing dialogue with physicians, patients and other stakeholders are essential to translating medical innovation into better care. She says this can help reshape treatment paradigms in rare diseases and…

Ipsen delivered strong performance in the third quarter of 2026, with total sales growth of 24.6% at constant exchange rates, driven by continued momentum across Oncology, Rare Disease and Neuroscience.

As the Ipsen team departs for #ESMO2026 in Madrid, one area I am particularly interested in is the growing role of real-world data in helping us understand cancer care beyond the clinical trial setting.

By Aurora Berra, Head of Global Patient Affairs.

Powerful screening tools, genomics and AI are reshaping how researchers identify potential targets for new medicines. Ipsen describes how its partnership with Foreseen Biotechnology helped advance the antibody drug conjugate IPN60300 into Phase I/II trials.

Science is at the heart of everything we do. It also comes with an environmental footprint, from the energy and water used in laboratories to the chemicals, equipment and materials required to advance our work.

Behind every job title is a human story.

Ipsen’s commitment to developing strong capabilities across its teams has been recognized with two Gold Awards at the 2026 Brandon Hall Excellence Awards, one of the leading international programs recognizing achievements in learning and talent development.

“In order to help all partners understand the value of a medicine, we provide the wrap-around support of data coming out of clinical trials.”

After 25 years working in oncology, Jon Travers understood the impact cancer can have on patients and their families. Throughout his career, he had been driven by the possibility of helping bring new treatments to the people who need them most.